US Stock MarketDetailed Quotes
LSTA Lisata Therapeutics
- 3.160
- +0.330+11.66%
Close Nov 1 16:00 ET
26.29MMarket Cap-1234P/E (TTM)
3.350High2.818Low60.61KVolume2.820Open2.830Pre Close190.50KTurnover0.87%Turnover RatioLossP/E (Static)8.32MShares3.83052wk High0.69P/B22.01MFloat Cap2.05052wk Low--Dividend TTM6.96MShs Float1350000.000Historical High--Div YieldTTM18.81%Amplitude1.950Historical Low3.142Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Lisata Therapeutics Stock Forum
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
Lisata Therapeutics (Nasdaq: LSTA) has entered into a sponsored research agreement with the University of Cincinnati to study certepetidecombined with bevacizumab for treating endometriosis. The research aims to leverage certepetide's selective targeting of endometrial tissue through surface integrin an...
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Haystack Oncology announced a research collaboration with Lisata Therapeutics Inc. This partnership aims to leverage Haystack's cutting-edge minimal residual disease (MRD) technology to assess the efficacy of innovative treatments for metastatic pancreatic cancer. $Lisata Therapeutics (LSTA.US)$
https://stockregion.app/p/therapeutics-company-announces-collaboration
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics (Nasdaq: LSTA) have announced a research collaboration to evaluate the efficacy of a pancreatic cancer therapy. Lisata will use Haystack's MRD™ technology to detect circulating tumor DNA (ctDNA) in a clinical study of certepetide plu...
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
Benzinga· 2 mins ago
No comment yet